We also acknowledge that medical therapy for heart failure continues to evolve (i.e., more patients are being prescribed sodium-glucose cotransporter-2 inhibitors and angiotensin-neprilysin inhibitors). This evidence concerns the gene SLC5A2 and heart failure.